RadioMedix, Inc. is a clinical-stage biotechnology company, based in Texas, focused on innovative targeted radiopharmaceuticals for diagnosis, monitoring, and therapy of cancer.
We commercialize radiopharmaceuticals for PET imaging and targeted alpha and beta-emitter therapy.
Our operations cover the entire value chain from drug discovery to sponsoring and conducting clinical trials to scale up manufacturing. RadioMedix is compliant with 21 CFR Parts 210,211,212.
Our Molecular Core Facility supports the synthesis, and the pre-clinical evaluation of our drugs and contract projects. Our cGMP Suite manufactures doses for Phase I-III clinical trials. Our state of the art commercial manufacturing site is prepared for scaled up and commercial grade production of radiolabeled drugs and isotopes (The Spica Center).
To improve patients life by providing innovative radiotheranostics and accelerating of discoveries in nuclear medicine.
At RadioMedix, Inc., our leadership team is dedicated to pioneering advancements in targeted radiopharmaceuticals for cancer diagnosis, monitoring, and therapy. Based in Texas, our clinical-stage biotechnology company thrives on innovation and excellence. Our team brings together a wealth of experience and expertise in the fields of radiopharmaceuticals, PET imaging, and targeted alpha and beta-emitter therapy.
At RadioMedix, Inc., we are at the forefront of innovation in targeted radiopharmaceuticals for cancer diagnosis, monitoring, and therapy. Our team is passionate about making a difference in the lives of patients through cutting-edge science and technology. We are always looking for talented and dedicated individuals to join our mission-driven team.
At Radiomedix, We utilize targeted radionuclide treatment to diagnose and treat patients. This theranostic approach allows for diagnosing patient maladies with precision and control of disease.
